The Maxim Group Analysts Give Cytosorbents Corp (CTSO) a $10.00 Price Target

The Maxim Group Analysts Give Cytosorbents Corp (CTSO) a $10.00 Price Target

A number of other equities analysts also recently commented on CTSO. B. Riley reiterated a buy rating and set a $11.25 target price on shares of Cytosorbents Corp in a research note on Monday, March 6th. Aegis reiterated a buy rating on shares of Cytosorbents Corp in a research note on Tuesday, March 7th. Finally, HC Wainwright boosted their target price on shares of Cytosorbents Corp from $11.50 to $13.00 and gave the stock a buy rating in a research note on Monday, March 6th. Five analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average price target of $13.45.

Maxim Group set a $10.00 price objective on Cytosorbents Corp (NASDAQ:CTSO) in a report released on Monday, May 22nd. The firm currently has a buy rating on the medical research company’s stock.

Cytosorbents Corp (NASDAQ CTSO) opened at 4.00 on Monday. The stock’s market cap is $112.43 million. Cytosorbents Corp has a 52 week low of $3.95 and a 52 week high of $6.90. The firm’s 50-day moving average price is $4.54 and its 200-day moving average price is $5.18. Cytosorbents Corp (NASDAQ:CTSO) last posted its quarterly earnings results on Monday, May 8th. The medical research company reported ($0.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.06. The business had revenue of $3.11 million during the quarter, compared to analyst estimates of $2.99 million. Equities analysts predict that Cytosorbents Corp will post ($0.28) earnings per share for the current fiscal year.

Cytosorbents Corp (NASDAQ CTSO) opened at 4.00 on Monday. The stock’s market cap is $112.43 million. Cytosorbents Corp has a 52 week low of $3.95 and a 52 week high of $6.90. The firm’s 50-day moving average price is $4.54 and its 200-day moving average price is $5.18. Several large investors have recently made changes to their positions in the stock. Skylands Capital LLC boosted its stake in shares of Cytosorbents Corp by 1,276.5% in the first quarter. Skylands Capital LLC now owns 316,600 shares of the medical research company’s stock worth $1,425,000 after buying an additional 293,600 shares during the last quarter. Sabby Management LLC acquired a new stake in shares of Cytosorbents Corp during the first quarter worth approximately $990,000. Cowen Group Inc. acquired a new stake in shares of Cytosorbents Corp during the first quarter worth approximately $248,000. Segantii Capital Management Ltd boosted its stake in shares of Cytosorbents Corp by 563.4% in the first quarter. Segantii Capital Management Ltd now owns 27,200 shares of the medical research company’s stock worth $122,000 after buying an additional 23,100 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Cytosorbents Corp by 3.9% in the first quarter. Vanguard Group Inc. now owns 567,116 shares of the medical research company’s stock worth $2,552,000 after buying an additional 21,312 shares during the last quarter. 6.07% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents Corp CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CTSO”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Cytosorbents Corp Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cytosorbents Corp and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment